These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Anamnestic studies in multiple sclerosis: a relationship between familial multiple sclerosis and neoplasia. Sibley WA; Bamford CR; Laguna JF Neurology; 1978 Sep; 28(9 Pt 2):125-8. PubMed ID: 568746 [TBL] [Abstract][Full Text] [Related]
23. Immune complexes and the complement factors C4 and C3 in cerebrospinal fluid and serum from patients with chronic progressive multiple sclerosis. Jans H; Heltberg A; Zeeberg I; Kristensen JH; Fog T; Raun NE Acta Neurol Scand; 1984 Jan; 69(1):34-8. PubMed ID: 6702418 [TBL] [Abstract][Full Text] [Related]
26. C1q microtiter plate ELISA system for detecting circulating immune complexes and its application of testing the sera in neurological diseases. Araga S; Irie H; Takahashi K Jpn J Exp Med; 1984 Feb; 54(1):23-7. PubMed ID: 6384588 [TBL] [Abstract][Full Text] [Related]
27. Analysis of circulating immune complexes in plasma of MS patients. Wiederkehr F; Büeler MR; Vonderschmitt DJ Schweiz Arch Neurol Psychiatr (1985); 1991; 142(2):126-9. PubMed ID: 1710383 [No Abstract] [Full Text] [Related]
28. Absence of brain antibodies in the sera of relapsing-remitting multiple sclerosis patients is not due to the formation of immune complexes. Henneberg AE; Elsner U; Kornhuber HH Acta Neurol Scand; 1993 Jun; 87(6):455-6. PubMed ID: 8356873 [TBL] [Abstract][Full Text] [Related]
29. Gene-environment interactions between HLA B7/A2, EBV antibodies are associated with MRI injury in multiple sclerosis. Zivadinov R; Weinstock-Guttman B; Zorzon M; Uxa L; Serafin M; Bosco A; Bratina A; Maggiore C; Grop A; Tommasi MA; Srinivasaraghavan B; Ramanathan M J Neuroimmunol; 2009 Apr; 209(1-2):123-30. PubMed ID: 19232441 [TBL] [Abstract][Full Text] [Related]
31. SNP mapping and candidate gene sequencing in the class I region of the HLA complex: searching for multiple sclerosis susceptibility genes in Tasmanians. Burfoot RK; Jensen CJ; Field J; Stankovich J; Varney MD; Johnson LJ; Butzkueven H; Booth D; Bahlo M; Tait BD; Taylor BV; Speed TP; Heard R; Stewart GJ; Foote SJ; Kilpatrick TJ; Rubio JP Tissue Antigens; 2008 Jan; 71(1):42-50. PubMed ID: 17971048 [TBL] [Abstract][Full Text] [Related]
32. Histocompatibility antigens in familial multiple sclerosis in a high-risk area of the disease. Kinnunen E; Koskimies S; Lagerstedt A; Wikström J J Neurol Sci; 1984 Aug; 65(2):147-55. PubMed ID: 6592288 [TBL] [Abstract][Full Text] [Related]
33. Genetic influence of the nonclassical major histocompatibility complex class I molecule MICB in multiple sclerosis susceptibility. Fernandez-Morera JL; Rodriguez-Rodero S; Tunon A; Martinez-Borra J; Vidal-Castineira JR; Lopez-Vazquez A; Rodrigo L; Rodrigo P; González S; Lahoz CH; Lopez-Larrea C Tissue Antigens; 2008 Jul; 72(1):54-9. PubMed ID: 18588574 [TBL] [Abstract][Full Text] [Related]
34. Epigenetics in multiple sclerosis susceptibility: difference in transgenerational risk localizes to the major histocompatibility complex. Chao MJ; Ramagopalan SV; Herrera BM; Lincoln MR; Dyment DA; Sadovnick AD; Ebers GC Hum Mol Genet; 2009 Jan; 18(2):261-6. PubMed ID: 19098025 [TBL] [Abstract][Full Text] [Related]
36. HLA profiles in multiple sclerosis suggest two forms of disease and the existence of protective haplotypes. Madigand M; Oger JJ; Fauchet R; Sabouraud O; Genetet B J Neurol Sci; 1982 Mar; 53(3):519-29. PubMed ID: 6978384 [TBL] [Abstract][Full Text] [Related]
37. Circulating immune complexes in multiple sclerosis. Relation to clinical and biological parameters. Davous P; Jacque CM; Grangeot-Keros L; Marteau R; Baumann N Biomedicine; 1978 May; 29(3):103-6. PubMed ID: 687746 [TBL] [Abstract][Full Text] [Related]